The company has launched its Clobazam oral suspension 2.5mg/mL after having received approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
Drug firm Lupin Friday said it has launched generic Clobazam oral suspension, used for treatment of seizures associated with a severe form of epilepsy, in the US market.
The company has launched its Clobazam oral suspension 2.5mg/mL after having received approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
The product is the generic version of Lundbeck Pharmaceuticals LLC's Onfi Oral Suspension, 2.5mg/mL, it added.
As per IQVIA MAT December 2018 data, Clobazam oral suspension 2.5mg/mL had annual sales of $253 million in the US, Lupin said.
"It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older," the company added.
Shares of Lupin Ltd closed at Rs 775.80 per scrip on BSE, down 4.32 per cent.
